Because cancer cells can be genetically different even a centimeter apart within the same tumor, a single targeting agent will inevitably miss some malignant tissue. The solution is a 'cocktail' of multiple tumor-targeted dyes, each targeting a different marker, to ensure visualization of virtually all cancer variants in a patient.

By treating patients before their tumors are surgically removed, Infinitopes can analyze the resected tissue. This provides direct evidence of CD8 T cell infiltration in response to the vaccine—a powerful, mechanistic proof-point that is impossible for competitors testing in later-stage patients.

The trend towards less invasive surgery using smaller incisions and endoscopes reduces a surgeon's ability to see and feel tissue directly. This loss of traditional tactile and visual feedback creates a critical need for new tools. Fluorescence-guided surgery is not just an improvement but a necessary replacement for these lost senses.

Traditional non-inferiority trials for reducing treatment are difficult to fund and execute. A proposed paradigm shift is to use superiority trial designs, where the burden of proof is on demonstrating that a higher dose or longer duration of therapy is actually better than a de-escalated approach.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

An experienced leader's ultimate due diligence for a radiopharmaceutical company was not the science on paper, but a single human scan. This image proves the drug goes to the tumor and not healthy organs, visually confirming the therapeutic window and de-risking the entire platform in one compelling piece of data.

The SUNRISE 2 trial's chemoradiation arm showed unexpectedly strong results. This is likely due to a protocol requiring a repeat resection (RIT-URBT) before randomization, which weeded out aggressive tumors and selected a patient population with a better prognosis, making the control arm unusually difficult to beat.

Fluorescence-guided surgery will evolve beyond simply lighting up tumors. Dr. Phil Low's team is developing different colored dyes to simultaneously highlight healthy, critical structures like nerves and ureters. This 'surgery by colors' approach aims to prevent accidental severing and reduce major complications like incontinence or impotence.

Clinical Complete Response (cCR), assessed by imaging and biopsy, is the primary endpoint for avoiding surgery in new trials. However, these tools are known to be unreliable, potentially missing up to 25% of residual post-mucosal tumors and leading to undertreatment.